Lack of association between hla–dr2 and clinical response to methotrexate in patients with rheumatoid arthritis

Authors

  • Graciela S. Alarcóan MD, MPH,

    Corresponding author
    1. University of Alabama at Birmingham, Birmingham
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    • 419 SRC, University of Alabama at Birmingham, Birmingham, AL 35294
    Search for more papers by this author
  • Lynn M. Billingsley MD,

    1. Johns Hopkins University School of Medicine, Baltimore
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author
  • Daniel O. Clegg MD,

    1. University of Utah School of Medicine, Salt Lake City
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author
  • Joe G. Hardin MD,

    1. University of South Alabama, Mobile
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author
  • John Klippel MD,

    1. National Institutes of Health, Bethesda
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author
  • Michael E. Luggen MD,

    1. University of Cincinnati, Cincinnati, OH
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author
  • Richard P. Polisson MD,

    1. Duke University Medical Center, Durham, NC
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author
  • Joyce Z. Singer MD,

    1. State University of New York, Down-state Medical Center, Brooklyn
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author
  • Lillian Szydlo MD,

    1. University of California, Los Angeles
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author
  • Robert F. Willkens MD,

    1. Harbor View Medical Center, Seattle, WA
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author
  • Ronald T. Acton PhD,

    1. University of Alabama at Birmingham, Birmingham
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author
  • Bruce O. Barger PhD,

    1. University of Alabama at Birmingham, Birmingham
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author
  • Stephen L. Dahl PharmD,

    1. University of Utah School of Medicine, Salt Lake City
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author
  • William J. Koopman MD

    1. University of Alabama at Birmingham, Birmingham
    2. Cooperative Systematic Studies of Rheumatic Diseases, the Division of Clinical Immunology and Rheumatology and the Immunogenetics Program, Department of Medicine, University of Alabama at Birmingham, and the Birmingham Veteran's Administration Medical Center, Birmingham
    Search for more papers by this author

Abstract

Recent studies have indicated an association between the HLA–DR2 phenotype and substantial response to methotrexate in patients with rheumatoid arthritis (RA). To further resolve this issue, we analyzed this relationship. Our data, obtained from a multicenter, double-blind study of rigorously assessed patients with RA, demonstrated that neither HLA–DR2 nor any other HLA–DR specificity is significantly associated with a substantial clinical response to methotrexate in patients with RA.

Ancillary